Article: CANTAB PHARMACEUTICALS REPORTS THIRD QUARTER RESULTS

 
CAMBRIDGE, England, Nov. 28 /PRNewswire/ -- Cantab Pharmaceuticals plc (Nasdaq: CNTBY) today announced financial results for the third quarter ended September 30, 1994. 
Revenues for the third quarter of 1994 totaled pounds sterling 683,000, increasing more than two-fold from 219,000 pounds for the same period in 1993.  For both periods, revenues were earned under the collaborative agreement with Baxter Healthcare Corp. (NYSE: BAX) relating to Cantab's LM-CD45 product development program for the prevention of kidney transplant rejection. 
Operating expenses for the third quarter of 1994 were 1.7 million pounds, compared to 1.1 million pounds for the same period in 1993. ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!